Abstract
Purpose
To investigate the preventive effect of celecoxib, a specific cyclooxygenase-2 (Cox-2) inhibitor, on the development of chemoresistance in breast cancer cell line, MCF-7, and explore the mechanism of the action.
Methods
Chemoresistance phenotype was established by treating MCF-7 cells with 0.05 μg/ml doxorubicin for 7 days, and then the effect of preventive chemoresistance was investigated by the combination of same dose of doxorubicin with 10 μM celecoxib. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay was used to assess cytostatic efficacy of doxorubicin and 50% inhibiting concentration (IC50) of MCF-7 cells. RT-PCR was performed to examine mRNA expression of multidrug resistance gene 1 (MDR1) and its transcription factors c-Jun and NF-κB. Western blotting analysis was performed to detect the expression of protein. Flow cytometry (FCM) was applied to analyze the expression and function of P-glycoprotein (P-gp). Electrophoretic gel mobility shift assay (EMSA) was performed to determine the DNA-binding activity of nuclear transcription factors AP-1 and NF-κB.
Results
Compared with sensitive MCF-7 cells, MDR1 and its transcription factors c-Jun and NF-κB were up-regulated at both mRNA level (P < 0.01) and protein level (P < 0.01) by treatment with 0.05 μg/ml doxorubicin for 7 days. After co-incubation with both the same dose of doxorubicin and 10 μM celecoxib for 7 days, both mRNA level and protein level of MDR1, c-Jun and NF-κB up-regulated by doxorubicin were partly reversed (P < 0.01); DNA-binding activity of nuclear transcription factors AP-1 and NF-κB were inhibited; and the function of P-gp was decreased (P < 0.01). When MCF-7 cells were treated with increasing doses of doxorubicin in the presence of 10 μM celecoxib, IC50 value of doxorubicin and doxorubicin plus 10 μM celecoxib was 0.67 ± 0.03 and 0.38 ± 0.04 μg/ml, respectively (P < 0.01).
Conclusion
Celecoxib effectively prevents the development of chemoresistance in breast cancer cell line MCF-7 induced by doxorubicin, which was partly involved in inhibiting the expression and DNA-binding activity of nuclear transcription factors AP-1 and NF-κB and downstream expression and function of P-gp. Furthermore, cytostatic efficacy of celecoxib and doxorubicin on MCF-7 cell was synergistic.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Explore related subjects
Discover the latest articles and news from researchers in related subjects, suggested using machine learning.References
Altorki NK, Keresztes RS, Port JL et al (2003) Celecoxib, a selective cyclooxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol 21:2645–2650
Awara WM, El Sisi AE, El Sayad ME et al (2004) The potential role of cyclooxygenase-2 inhibitors in the treatment of experimentally-induced mammary tumour: does celecoxib enhance the anti-tumour activity of doxorubicin? Pharmacol Res 50:487–498
Bentires Alj M, Barbu V, Fillet M et al (2003) NF-kappaB transcription factor induces drug resistance through MDR1 expression in cancer cells. Oncogene 22:90–97
Chen GK, Sale S, Tan T et al (2004) CCAAT/enhancer-binding protein beta (nuclear factor for interleukin 6) transactivates the human MDR1 gene by interaction with an inverted CCAATbox in human cancer cells. Mol Pharmacol 65:906–916
Cianchi F, Cortesini C, Fantappie O et al (2004) Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Clin Cancer Res 10:2694–2704
Dannenberg AJ, Subbaramaiah K (2003) Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise. Cancer Cell 4:431–436
Daschner PJ, Ciolino HP, Plouzek CA et al (1999) Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells. Breast Cancer Res Treat 53:229–240
Fantappie O, Masini E, Sardi I et al (2002) The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 35:843–852
Kang HK, Lee E, Pyo H et al (2005) Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 4:1358–1363
Karin M, Liu Z, Zandi E (1997) AP-1 function and regulation. Curr Opin Cell Biol 9:240–246
Kim SH, Lee SH, Kwak NH et al (1996) Effect of the activated Raf protein kinase on the human multidrug resistance 1 (MDR1) gene promoter. Cancer Lett 98:199–205
Komaki R, Liao Z, Milas L (2004) Improvement strategies for molecular targeting: cyclooxygenase-2 inhibitors as radiosensitizers for non-small cell lung cancer. Semin Oncol 31:47–53
Labialle S, Gayet L, Marthinet E et al (2002) Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64:943–948
Leonessa F, Clarke R (2003) ATP binding cassette transporters and drug resistance in breast cancer. Endocr Relat Cancer 10:43–73
Liao Z, Milas L, Komaki R et al (2003) Combination of a COX-2 inhibitor with radiotherapy or radiochemotherapy in the treatment of thoracic cancer. Am J Clin Oncol 26:S85–S91
McGinty A, Chang YWE, Sorokin A et al (2000) Cyclooxygenase-2 expression inhibits trophic withdrawal apoptosis in nerve growth factor-differentiated PC12 cells. J Biol Chem 275(16):12095–12101
Murata H, Tsuji S, Tsujii M et al (2004) Promoter hypermethylation silences cyclooxygenase-2 (Cox-2) and regulates growth of human hepatocellular carcinoma cells. Lab Invest 84:1050–1059
Puhlmann U, Ziemann C, Ruedell G et al (2005) Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 312:346–354
Shain KH, Dalton WS (2001) Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 1:69–78
Shin YK, Park JS, Kim HS et al (2005) Radiosensitivity enhancement by celecoxib, a cyclooxygenase (COX)-2 selective inhibitor, via COX-2-dependent cell cycle regulation on human cancer cells expressing differential COX-2 levels. Cancer Res 65:9501–9509
Sorokin A (2004) Cyclooxygenase-2: potential role in regulation of drug efflux and multidrug resistance phynotype. Curr Pharm Des 10:647–657
Tan B, Piwnica-Worms D, Ratner L (2000) Multidrug resistance transporters and modulation. Curr Opin Oncol 12:450–458
Tegeder I, Niederberger E, Israr E et al (2001) Inhibition of NF-kappaB and AP-1 activation by R-and S-flurbiprofen. FASEB J 15:2–4
Trifan OC, Hla T (2003) Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 7:207–222
Van Wijngaarden J, van Beek E, van Rossum G et al (2007) Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kB-mediated increase of intracellular doxorubicin accumulation. Eur J Cancer 43:433–442
Wilgus TA, Breza TS Jr, Tober KL et al (2004) Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. J Invest Dermatol 122:1488–1494
Zrieki A, Farinotti R, Buyse M (2008) Cyclooxygenase Inhibitors down regulate P-glycoprotein in Human colorectal caco-2 cell line. Pharm Res 25:1991–2001
Conflict of interest statement
None.
Author information
Authors and Affiliations
Corresponding author
Additional information
C. Chen and H. L. Shen have contributed equally to this study and should be considered as co-first authors.
Rights and permissions
About this article
Cite this article
Chen, C., Shen, H.L., Yang, J. et al. Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib. J Cancer Res Clin Oncol 137, 9–17 (2011). https://doi.org/10.1007/s00432-010-0854-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-010-0854-3